A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma

The present phase II study has demonstrated that augmenting neutrophil function by the addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin lymphoma while retaining the excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population for whom therapeutic options are limited owing to poor tolerance.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2017 Category: Hematology Authors: Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri Tags: Original Study Source Type: research